Why is Orchid Pharma falling/rising?

As of 21-Aug, Orchid Pharma Ltd's stock price is currently at 785.15, reflecting an increase of 27.05 or 3.57%. The stock has shown a positive performance today, outperforming its sector by 3.11% and reaching an intraday high of Rs 802.5, which is a 5.86% increase. Over the past week, the stock has gained 5.04%, and over the past month, it has risen by 8.75%. However, despite these short-term gains, the company has faced significant challenges, including a weak long-term fundamental strength indicated by an average Return on Equity (ROE) of 4.68% and a concerning EBIT to Interest ratio of 1.99. The company has reported negative results for the last three consecutive quarters, with a notable decline in operating profit of -19.64%, which has likely contributed to investor caution despite the recent price increase. Broader market context shows that while Orchid Pharma has outperformed the Sensex in the short term, with a 1-week return of +5.04% compared to the Sensex's +1.74%, it has significantly underperformed over the longer term. Year-to-date, the stock has decreased by 56.79%, while the Sensex has gained 4.94%. This stark contrast highlights the ongoing struggles of Orchid Pharma, particularly in light of its declining profitability and high valuation metrics, which may deter long-term investors. The high institutional holdings at 20.82% suggest some level of confidence from more sophisticated investors, but the overall negative financial indicators and recent poor performance may overshadow these positive aspects.